My take on it: The company has been on track with
Post# of 5066
Posted On: 09/27/2013 10:51:29 AM
.jpg)
My take on it:
The company has been on track with their schedule and then got off track because of the FDA. Keep in mind, they had no clue that the FDA would come back and ask for more animal studies. The company could not have foreseen this.
That's about all the good I can come up with. The disturbing issue is .... Koos invested about $120K (to buy 60mil shares) maybe a month ago. Did he know then about the FDA request for more studies? Then a month later, 3 or 4 promos come out that costs total around that same amount. At the same time the company releases info that knowingly will hurt the PPS. Were the promos done to minimize the price drop? Were the promos done to benefit a select few that could sell shares in the AM before the majority had to digest the news?
From the CEO standpoint, you were given news of a delay in approval. You then have to find someone who will be able to run the pre-clinicals in an effective manner to satisfy the FDA requirements. Why not your own CSO? Then, you have to figure out how to let the news out and minimize the PPS drop. I think who paid for those promos will have the key to knowing what the truth of the matter is. But, from the CEO standpoint, I think he made a calculated risk knowing the FDA approval was within the next year and having the SEC investigate the company before the approval would be detrimental, so why would anyone make a complaint to the SEC before then?
Koos has been sued numerous times and has settled with people by giving shares instead of cash. He has a history of sketchy manipulation and business practices. This does not bode well for the company, even though the science is revolutionary.
I would love to know the real reason why the other executive was fired during the summer.
The company has been on track with their schedule and then got off track because of the FDA. Keep in mind, they had no clue that the FDA would come back and ask for more animal studies. The company could not have foreseen this.
That's about all the good I can come up with. The disturbing issue is .... Koos invested about $120K (to buy 60mil shares) maybe a month ago. Did he know then about the FDA request for more studies? Then a month later, 3 or 4 promos come out that costs total around that same amount. At the same time the company releases info that knowingly will hurt the PPS. Were the promos done to minimize the price drop? Were the promos done to benefit a select few that could sell shares in the AM before the majority had to digest the news?
From the CEO standpoint, you were given news of a delay in approval. You then have to find someone who will be able to run the pre-clinicals in an effective manner to satisfy the FDA requirements. Why not your own CSO? Then, you have to figure out how to let the news out and minimize the PPS drop. I think who paid for those promos will have the key to knowing what the truth of the matter is. But, from the CEO standpoint, I think he made a calculated risk knowing the FDA approval was within the next year and having the SEC investigate the company before the approval would be detrimental, so why would anyone make a complaint to the SEC before then?
Koos has been sued numerous times and has settled with people by giving shares instead of cash. He has a history of sketchy manipulation and business practices. This does not bode well for the company, even though the science is revolutionary.
I would love to know the real reason why the other executive was fired during the summer.
(0)
(0)